MAIA Biotechnology (MAIA) said Monday its investigational telomere-targeting agent THIO received a rare pediatric disease designation from the Food and Drug Administration to treat pediatric-type diffuse high-grade gliomas.
The company partnered with Only Orphans Cote for THIO's designation request, it added.
MAIA said that THIO is currently in clinical development for evaluating its activity in non-small cell lung cancer.
Shares of the company were up 7% in recent Monday trading.
Price: 2.14, Change: +0.14, Percent Change: +7.00
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。